Edopain300 mg

Edopain 300 mg is indicated- For acute and long-term use in the management of signs and symptoms: Osteoarthritis, Rheumatoid arthritis For the management of acute pain Acute gout

Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Edopain 300 mg is a non-steroidal anti-inflammatory drug (NSAID). It inhibits the formation of prostaglandins. The inhibition of prostaglandin synthesis observed with Edopain 300 mg differs from that of other NSAIDs. Studies in human cell models have confirmed that Edopain 300 mg is selective for the inhibition of COX-2. Experiments have shown Edopain 300 mg to have marked anti-inflammatory activity, being more potent than several clinically established NSAIDs.

Carefully consider the potential benefits and risks of Edopain 300 mg and other treatment options before deciding to use Edopain 300 mg capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.After observing the response to initial therapy with Edopain 300 mg capsules, the dose and frequency should be adjusted to suit an individual patient's needs.Dosage adjustment of Edopain 300 mg is generally not required in patients with mild to moderate renal impairment. Edopain 300 mg should be used with caution in such patients, because, as with other NSAIDs, they may further decrease renal function in some patients with impaired renal function.Analgesia: The recommended total daily dose of Edopain 300 mg for acute pain is up to 1000 mg, given as 200 to 400 mg every 6 to 8 hours. Doses of Edopain 300 mg greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose is 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day may suffice for long-term administration. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.In chronic conditions, a therapeutic response to therapy with Edopain 300 mg is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.

Adults and over 18 years: Edopain 300 mg 300 mg capsule: 600 mg daily in 1-2 divided doses Edopain 300 mg 600 mg ER tablet: Once daily Pediatric: Safety and effectiveness in pediatric patients below the age of 18 years have not been established.

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. When Edopain 300 mg is administered with Aspirin, its protein binding is reduced, although the clearance of free Edopain 300 mg is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Edopain 300 mg and Aspirin is not generally recommended because of the potential of increased adverse effects.

Edopain 300 mg is contraindicated in patients with known hypersensitivity to Edopain 300 mg. Edopain 300 mg should not be given to patients who have experienced asthma, urticaria or other allergic type reactions after taking Aspirin or other NSAIDs.

The common side effects of Edopain 300 mg involve the gastrointestinal system. It can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, Gl ulcers, vomiting. Other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc.

Pregnancy: There are no adequate and well-controlled studies in pregnant women. It should be use in pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: It is not known whether Edopain 300 mg is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.

Edopain 300 mg should be given with caution in patients with severe hepatic reactions, pre existing asthma, fluid retention, hypertension or heart failure. If clinical sings and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash etc.), it should be discontinued.

Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain which are generally reversible with supportive care.

Do not store above 30°C. Keep away from light and out of the reach of children.

Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Similar to other NSAIDs, the anti-inflammatory effects of Edopain 300 mg result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Edopain 300 mg binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Edopain 300 mg was previously thought to be a non-selective COX inhibitor, but it is now known to be 5-50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

There are no adequate and well-controlled studies in pregnant women. It should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Edopain 300 mg is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.